Neurexin/Neuroligin Synaptic Adhesion Modulator Therapy in Neurodegeneration

Neurexin/Neuroligin Synaptic Adhesion Modulator Therapy in Neurodegeneration

Overview

Neurexins (NRXN1/2/3) and neuroligins (NLGN1/2/3/4X/4Y) are a conserved pair of synaptic adhesion molecules that form trans-synaptic bridges linking presynaptic and postsynaptic terminals. These proteins are central to synapse formation, specification, maintenance, and plasticity. Disruption of neurexin-neuroligin (NRXN-NLGN) complexes has been implicated across a broad spectrum of neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), CBS/PSP, autism spectrum disorder (ASD), and schizophrenia [@sudhof2008].

The NRXN-NLGN complex represents a compelling therapeutic target because it serves as the master organizer of synaptic architecture — directing where neurotransmitter vesicles fuse, which receptors cluster, and how synapses are maintained over decades of neuronal activity. Restoring or enhancing NRXN-NLGN function offers a strategy to preserve synaptic integrity that is upstream of, and complementary to, disease-specific pathological cascades like amyloid-beta, tau, and alpha-synuclein.

This mechanism page covers the molecular biology of neurexins and neuroligins, their established roles in neurodegeneration across multiple diseases, and the therapeutic strategies — including small molecules, gene therapy, biologics, and cell-based approaches — being developed to target these complexes.

Molecular Architecture

Neurexin Family

Neurexin/Neuroligin Synaptic Adhesion Modulator Therapy in Neurodegeneration

Overview

Neurexins (NRXN1/2/3) and neuroligins (NLGN1/2/3/4X/4Y) are a conserved pair of synaptic adhesion molecules that form trans-synaptic bridges linking presynaptic and postsynaptic terminals. These proteins are central to synapse formation, specification, maintenance, and plasticity. Disruption of neurexin-neuroligin (NRXN-NLGN) complexes has been implicated across a broad spectrum of neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), CBS/PSP, autism spectrum disorder (ASD), and schizophrenia [@sudhof2008].

The NRXN-NLGN complex represents a compelling therapeutic target because it serves as the master organizer of synaptic architecture — directing where neurotransmitter vesicles fuse, which receptors cluster, and how synapses are maintained over decades of neuronal activity. Restoring or enhancing NRXN-NLGN function offers a strategy to preserve synaptic integrity that is upstream of, and complementary to, disease-specific pathological cascades like amyloid-beta, tau, and alpha-synuclein.

This mechanism page covers the molecular biology of neurexins and neuroligins, their established roles in neurodegeneration across multiple diseases, and the therapeutic strategies — including small molecules, gene therapy, biologics, and cell-based approaches — being developed to target these complexes.

Molecular Architecture

Neurexin Family

Neurexins are presynaptic cell adhesion molecules encoded by three genes (NRXN1, NRXN2, NRXN3) in mammals. They are among the largest genes in the genome due to extensive alternative splicing [@bellen2010].

| Gene | Chromosome | Isoforms | Primary Expression |
|------|------------|----------|-------------------|
| NRXN1 | 2p16.3 | α, β (1000+ splice variants) | Cortex, hippocampus, cerebellum |
| NRXN2 | 14q31.1 | α, β | Broad brain expression |
| NRXN3 | 6q16.1 | α, β | Cortex, basal ganglia |

α-Neurexin is the longer isoform with six LNS (laminin, neurexin, sex-hormone binding globulin) domains separated by EGF-like sequences, while β-neurexin has a shorter extracellular region with a single LNS domain. Both isoforms anchor to the presynaptic membrane via a single transmembrane domain and possess a short cytoplasmic tail that interacts with presynaptic scaffolding proteins including CASK, Mints, and synaptotagmin [@sudhof2017].

The alternative splicing of neurexins is remarkably complex — over 1000 distinct splice isoforms have been documented for NRXN1 alone. Alternative splicing occurs at two canonical sites (SS#2 and SS#3), creating a "molecular code" that determines which neuroligin isoforms and other partners each neurexin variant can bind. This combinatorial diversity allows neurexins to specify synaptic properties across different neuronal populations and brain regions [@sudhof2017].

Neuroligin Family

Neuroligins are postsynaptic cell adhesion molecules encoded by five genes (NLGN1, NLGN2, NLGN3, NLGN4X, NLGN4Y) in humans. Each neuroligin is a single-pass transmembrane protein with a large extracellular acetylcholinesterase-like (AChE-like) domain that mediates binding to neurexins [@dean2003].

| Gene | Chromosome | Synapse Type | Key Features |
|------|------------|--------------|--------------|
| NLGN1 | 3q26.31 | Excitatory (glutamatergic) | PSD-95 interacting, AMPA/NMDA receptor linked |
| NLGN2 | 17p13.1 | Inhibitory (GABAergic/glycinergic) | Gephyrin interacting, GABA_A receptor linked |
| NLGN3 | Xq13.1 | Both excitatory/inhibitory | Broad expression, ASD-linked |
| NLGN4X | Xp22.33 | Both | Highly ASD-associated |
| NLGN4Y | Yq11.21 | Both | Testis-expressed, CNS function uncertain |

NLGN1 is enriched at excitatory synapses where it interacts with PSD-95 and recruits AMPA and NMDA receptors. NLGN2 is preferentially localized at inhibitory synapses, where it recruits gephyrin to anchor GABA_A and glycine receptors. Recent work by Südhof and colleagues (2025) demonstrated that NLGN1 and NLGN2 operate through distinct molecular mechanisms to regulate their respective synapse types — NLGN1 controls postsynaptic differentiation through PSD-95, while NLGN2 uses a gephyrin-dependent pathway, despite both binding neurexins and activating similar intracellular signaling [@sudhof2025].

The Trans-Synaptic Bridge

The NRXN-NLGN complex forms a heterophilic trans-synaptic adhesion unit that bridges the presynaptic and postsynaptic cleft (~20 nm gap):

Interaction Partners Beyond NRXN-NLGN

Beyond the canonical NRXN-NLGN interaction, both protein families engage additional synaptic partners that extend their functional repertoire:

Neurexin Partners:

• Dystroglycan — via α-neurexin LNS6 domain
• Neurexophilins — secreted neuropeptide-like proteins
• LRRTMs (leucine-rich repeat transmembrane proteins) — postsynaptic partners competing with neuroligins
• Cerebellin — secreted protein that forms a ternary complex with neurexins
• Contactin-3 (CNTN3) — coordinates with neurexin-NLGN-SHANK3 scaffold [@suzuki2023]

• SHANK1/2/3 — postsynaptic scaffold linking to actin cytoskeleton
• Scaffolding proteins — PSD-95 (NLGN1), gephyrin (NLGN2)
• Signaling proteins — neuroligins activate src family kinases and other intracellular pathways
• Retromer — NLGN2-dependent synapse elimination requires retromer-mediated trafficking [@bemben2015]

Role in Neurodegeneration

Alzheimer's Disease

NRXN1 dysfunction is increasingly recognized in AD pathophysiology. Reichelt et al. (2022) demonstrated that NRXN1 alternative splicing patterns are altered in AD brains, serving as a marker of synaptic dysfunction [@reichelt2022]. Specifically, the balance between excitatory and inhibitory neurexin splice isoforms shifts in AD, potentially contributing to the excitatory/inhibitory (E/I) imbalance observed in the disease.

Proteomic studies of AD synapses reveal reduced levels of neurexin and neuroligin proteins in affected brain regions. Shen et al. (2018) identified neurexins among the presynaptic proteins downregulated in AD temporal cortex, correlating with cognitive decline [@shen2018]. The amyloid-beta oligomers that drive early synaptic dysfunction in AD may preferentially disrupt NRXN-NLGN complexes, as these proteins concentrate at the synaptic cleft where AβOs bind neuronal membranes.

A 2024 study showed that DSCR1 (Down syndrome critical region gene 1) long isoform overexpression — a feature of both Down syndrome and AD — induces synaptic dysfunction by disrupting neurexin-neuroligin signaling, providing a direct mechanistic link between chromosomal risk factors and synaptic adhesion impairment [@arstikaitis2008].

The NRXN-NLGN pathway intersects with multiple AD-relevant mechanisms:

• Tau pathology phosphorylates and mislocalizes synaptic proteins including those involved in NRXN-NLGN trafficking
• Microglial pruning may preferentially eliminate synapses with compromised NRXN-NLGN adhesion
• Complement activation tags NRXN-NLGN-depleted synapses for microglial phagocytosis

Parkinson's Disease

West et al. (2023) demonstrated direct involvement of NRXN1 and NLGN1 in Parkinson's disease synaptic pathology [@west2023]. In PD models, alpha-synuclein aggregates disrupt the localization and function of neurexin-neuroligin complexes at dopaminergic and striatal synapses, contributing to the synaptic dysfunction that precedes motor symptoms.

The presynaptic dysfunction in PD — including impaired dopamine release, reduced vesicle cycling, and synaptic terminal loss — may be partly mediated through disrupted neurexin interactions with their postsynaptic partners. At dopaminergic synapses, NRXN-NLGN complexes help organize the precise release machinery required for neuromodulatory rather than fast neurotransmitter signaling, making them particularly vulnerable to alpha-synuclein toxicity.

Additionally, PINK1 and parkin mutations (familial PD genes) affect synaptic vesicle trafficking proteins that physically interact with neurexin scaffolds, suggesting convergent pathways between familial PD genes and synaptic adhesion complexes.

Amyotrophic Lateral Sclerosis (ALS)

NLGN mutations are documented in ALS patients, particularly NLGN1 and NLGN3 variants that may contribute to ALS-FTD spectrum disorders. The overlap between ALS and FTD — which share TDP-43 pathology, C9orf72 expansions, and synaptic dysfunction — implicates NRXN-NLGN disruption as a shared mechanism.

Neurexin expression is altered in spinal cord motor neurons affected by ALS, and the progressive loss of neuromuscular junctions in ALS models involves disrupted synaptic adhesion. At corticospinal synapses, TDP-43 pathology disrupts RNA processing of neurexin splice variants, potentially altering synaptic specificity.

The role of neurexins in regulating both excitatory (glutamatergic corticomotor) and inhibitory (Renshaw cell-mediated Renshaw) synapses makes their dysfunction a plausible contributor to the spasticity and fasciculations characteristic of ALS.

Frontotemporal Dementia (FTD)

NLGN3 and NLGN4 mutations are enriched in FTD patients, particularly those with behavioral variant FTD (bvFTD). The overlap between FTD and ALS at the genetic and pathological level extends to the NRXN-NLGN system — C9orf72 repeat expansions disrupt synaptic gene expression including neurexin and neuroligin transcripts.

TDP-43 pathology in FTD affects the alternative splicing of neurexins, which is particularly important given neurexins' thousands of splice isoforms. Loss of TDP-43 function leads to aberrant splicing patterns that may produce non-functional neurexin variants, contributing to the synaptic failure observed in FTD.

Corticobasal Syndrome and Progressive Supranuclear Palsy (CBS/PSP)

4R tauopathies (CBS, PSP) show synaptic dysfunction involving the NRXN-NLGN complex. Tau pathology disrupts the trafficking of neuroligins to the postsynaptic membrane, and the selective vulnerability of certain neuronal populations (e.g., striatal and brainstem nuclei in PSP, cortical and basal ganglia neurons in CBS) may reflect differential dependence on NRXN-NLGN complexes for synaptic maintenance.

The tau-mediated disruption of microtubule-based transport impairs the delivery of NRXN-NLGN components to synaptic sites, potentially leading to "synaptic starvation" even before overt neurodegeneration begins.

Neurodevelopmental Links to Later Neurodegeneration

The observation that ASD-linked mutations in NRXN and NLGN genes predispose to early-onset neurodegeneration suggests a two-hit model: a developmental deficit in synaptic wiring is later compounded by age-related protein aggregation, oxidative stress, or microglial activation. Individuals with NRXN/NLGN mutations may enter mid-life with a "synaptic reserve" that is more rapidly depleted than in unaffected individuals.

Therapeutic Targeting Strategies

Small Molecule Approaches

Enhancing NRXN-NLGN binding affinity: The extracellular interaction between neurexin and neuroligin involves a protein-protein interaction surface that, while large, may be amenable to stabilization by small molecules. High-throughput screens have identified compounds that enhance neurexin-neuroligin binding in vitro, though brain penetration remains a challenge.

Targeting alternative splicing: Since alternative splicing governs neurexin binding specificity, compounds that modulate the splicing factors (e.g., PTBP2, RBFOX1/2) that regulate NRXN splice sites could shift the isoform repertoire toward more stable synaptic adhesion. Antisense oligonucleotides (ASOs) targeting NRXN splicing are in preclinical development.

Intracellular signaling modulators: NLGNs activate src family kinases and other signaling pathways. Small molecules that enhance downstream signaling (e.g., src kinase activators) could compensate for reduced NLGN surface expression in neurodegeneration.

Gene Therapy

AAV-mediated NLGN expression: Adeno-associated virus (AAV) vectors encoding NLGN1 or NLGN2 under neuronal promoters could restore NLGN levels in affected neurons. Studies in rodent models have shown that AAV-NLGN2 delivery can rescue synaptic deficits and improve behavioral outcomes in neuroligin knockdown animals.

CRISPR-based correction: For patients with loss-of-function mutations in NRXN or NLGN genes, CRISPR-Cas9 base editing or prime editing could correct disease-causing variants. Proof-of-concept has been demonstrated for NLGN3 correction in human neurons derived from patient iPSCs [@tayler2023].

Gene replacement for structural mutations: For NRXN1 deletions (which cause haploinsufficiency), AAV-mediated expression of a functional NRXN1 construct could restore dosage.

Biologic Therapies

Bridge-building biologics: Engineered synthetic bridge proteins — combining a neurexin-binding domain with a neuroligin-binding domain — could function as "molecular glue" to stabilize compromised synapses. These bifunctional proteins could be administered systemically if designed to cross the blood-brain barrier or delivered via intrathecal injection.

Monoclonal antibodies: Antibodies targeting the extracellular domains of NRXN or NLGN could modulate their adhesive properties. Agonist antibodies that cluster NLGNs at the postsynaptic membrane might enhance synapse stability.

Protein replacement: Recombinant soluble NLGN extracellular domains (lacking the transmembrane and intracellular regions) could act as competitive inhibitors of pathological synapse elimination while preserving synaptic adhesion functions.

Cell-Based Approaches

iPSC-derived neuron replacement: Patient-derived neurons with corrected NRXN/NLGN genes, differentiated into the appropriate neuronal subtype (e.g., cortical pyramidal neurons for AD, dopaminergic neurons for PD, motor neurons for ALS), could be transplanted to replace lost cells. This approach addresses both the neurodegenerative component and the developmental synaptic adhesion deficit.

Exosome-mediated delivery: Engineered exosomes carrying NRXN or NLGN coding sequences could deliver therapeutic proteins across the blood-brain barrier via systemic administration.

Target Discovery and Validation

Splice isoform-specific targeting: The extraordinary diversity of neurexin splice isoforms creates opportunities for isoform-specific therapeutics. Identifying which splice variants are most affected in specific diseases (e.g., AD-associated NRXN1 SS#3 exon inclusion patterns) enables precision targeting.

Interacting protein complexes as targets: The CNTN3-NRXN-NLGN-SHANK3 scaffold [@suzuki2023] and the CNTN3-NRXN-RAB3A vesicle trafficking pathway [@fujita2022] represent additional nodes for therapeutic intervention. Stabilizing these broader complexes could provide more robust synaptic support than targeting NRXN-NLGN alone.

High-content screening: Human iPSC-derived neurons with NRXN/NLGN mutations can be used in high-throughput screens to identify compounds that restore synaptic connectivity, using synaptic density markers (synapsin, PSD-95) as readouts.

Clinical Pipeline

| Approach | Stage | Target | Indications | Notes |
|----------|-------|--------|-------------|-------|
| AAV-NLGN2 | Preclinical | NLGN2 overexpression | ALS, FTD | Synaptic stabilization |
| ASO for NRXN splicing | Discovery | NRXN alternative splicing | AD | Modulate splice isoform balance |
| Synthetic bridge proteins | Lead optimization | NRXN-NLGN complex | AD, PD, ALS | Stabilize trans-synaptic adhesion |
| CRISPR-NLGN correction | Preclinical | NLGN3 point mutations | ASD, ALS | iPSC models validated |
| Src kinase activators | Lead optimization | NLGN downstream signaling | Broad neurodegeneration | Oral CNS-penetrant compounds |
| AAV-NRXN1 | Discovery | NRXN1 haploinsufficiency | NRXN1 deletion syndrome | In vivo efficacy in rodents |

Biomarkers for Target Engagement

Fluid biomarkers:

• Soluble NLGN1/2 in CSF (reduced in AD/PD)
• Extracellular vesicle-associated NRXN fragments

• SV2A PET for synaptic density (indirect read-out of NRXN-NLGN function)
• Glutamate/GABA PET for E/I balance correction

• EEG gamma oscillation changes (reflecting excitatory/inhibitory balance)
• TMS plasticity measures for synaptic function

Cross-Links to Related Pages

Gene Pages

• [NRXN1 Gene](/genes/nrxn1) — Neurexin-1, implicated in AD and PD synaptic dysfunction
• [NRXN2 Gene](/genes/nrxn2) — Neurexin-2, neurodevelopmental disorder associations
• [NRXN3 Gene](/genes/nrxn3) — Neurexin-3, ASD risk gene
• [NLGN1 Gene](/genes/nlgn1) — Neuroligin-1, excitatory synapse organizer
• [NLGN2 Gene](/genes/nlgn2) — Neuroligin-2, inhibitory synapse organizer
• [NLGN3 Gene](/genes/nlgn3) — Neuroligin-3, X-linked, ASD and ALS
• [NLGN4X Gene](/genes/nlgn4x) — Neuroligin-4X, highly ASD-associated

Related Mechanism Pages

• [Synaptic Failure in Neurodegeneration](/mechanisms/synaptic-failure-pathway)
• [Synaptic Dysfunction in 4R Tauopathies](/mechanisms/synaptic-dysfunction-4r-tauopathies)
• [Complement-Mediated Synapse Loss](/mechanisms/complement-mediated-synapse-loss)
• [Microglial Synaptic Pruning Dysregulation](/mechanisms/microglial-synaptic-pruning-dysregulation)
• [CBS Synaptic Dysfunction](/mechanisms/cbs-synaptic-dysfunction)

Related Entity Pages

• [CNTN3 — Contactin 3](/genes/cntn3) — Coordinates NRXN-NLGN-SHANK3 scaffold
• [Thomas C. Südhof](/researchers/thomas-sudhof) — Nobel laureate, NRXN/NLGN discovery

Company Pages

• [Alzheimer's Disease Synaptic Repair and Neuroprotection Companies](/companies/ad-synaptic-repair-neuroprotection-companies) — Pipeline overview including synaptic adhesion targets

Open Questions

See Also

• [Alzheimer's Disease — Mechanisms](/diseases/alzheimers-disease)
• [Parkinson's Disease — Mechanisms](/diseases/parkinsons-disease)
• [ALS — Mechanisms](/diseases/amyotrophic-lateral-sclerosis)
• [Frontotemporal Dementia — Mechanisms](/diseases/frontotemporal-dementia)
• [Synaptic Adhesion Complexes](/mechanisms/synaptic-adhesion)
• [Neurodevelopmental Disorder Mechanisms](/mechanisms/neurodevelopmental-disorders)
• [Therapeutic Approaches Index](/therapeutics)